PLCE1 Polymorphism and Upper Gastrointestinal Cancer Risk: A Meta-Analysis

Abstract

BackgroundIn recent years, the PLCE1 rs2274223 polymorphism has been extensively investigated as a potential risk factor for upper gastrointestinal cancers, including squamous cell carcinoma (ESCC) and gastric cancer. However, the results of these studies have been inconsistent.MethodsA meta-analysis of 13 case-control studies was performed including more than 11,000 subjects with genotyped PLCE1 rs2274223 polymorphisms. Odds ratios (OR) with 95% confidence intervals (CI) were employed to assess the association of the PLCE1 rs2274223 polymorphism with a susceptibility to ESCC or gastric cancer.ResultsA statistically significant increase in the risk of ESCC was associated with the PLCE1 rs2274223 polymorphism. This included the homozygous genetic model (OR = 1.46), heterozygous genetic model (OR = 1.25) and allelic genetic model (OR = 1.23). Similar results were consistently found for gastric cancer. In a subgroup analysis, the PLCE1 rs2274223 polymorphism was found to be a very sensitive marker for gastric cardia cancer as shown by the homozygous genetic model (OR = 2.23), heterozygous genetic model(OR = 1.59) and allelic genetic model (OR = 1.47). The risk associations of all of the gastric cardia cancer models were statistically significant. In contrast, none of the genetic models for non-cardia gastric cancer were significant.ConclusionsIn this meta-analysis, the PLCE1 rs2274223 polymorphism was confirmed to have a statistically significant association with an increasing risk of ESCC and gastric cancer. The increase risk was especially observed for gastric cardia cancer.

PLCE1 mRNA and Protein Expression and Survival of Patients with Esophageal Squamous Cell Carcinoma and Gastric Adenocarcinoma

“…Reduced PLCE1 expression appeared to be more consistent in GC tumors than ESCC tumors, which is partly consistent with the stronger genetic effect of PLCE 1 SNPs in GC, particularly in GCA, as compared with ESCC (6,34). However, the association of PLCE1 SNPs with GNCA was not significant (6,34). The differentially altered PLCE1 expression in UGI cancers warrants further investigation.…”

Ezrin silencing remodulates the expression of Phosphoinositide‐specific Phospholipase C enzymes in human osteosarcoma cell lines

“…A number of evidences indicate that PI-PLC ε might favour cancer initiation and/or progression, as in bladder (Cheng et al 2011;Ou et al 2010), murine skin (Bai et al 2004, Oka 2010, Li et al 2009), head and neck cancers (Bourguignon et al 2006). The rs 2274223 polymorphism was significantly associated to increased risk of squamous cell carcinoma and gastric cancer (Hao 2013 By contrast, tumour suppressive role for PI-PLC ε was recently suggested in Ras-triggered cancers (Martins et al 2014). Our present results suggest the existence of a relationship between Ezrin and PI-PLC ε, corroborated by microscopy observations detecting focal and partial cytoplasmic colocalization (Figure 3).…”

Common Genetic Variants of PSCA, MUC1 and PLCE1 Genes are not Associated with Colorectal Cancer

“…Unfortunately, due to the lack of studies, no comparison for our results can be made in terms of other Caucasian populations. GWAS conducted on gastric and esophageal cancer patients have shown an evident role of rs2274223 gene polymorphism (Abnet et al, 2010;Wang et al, 2010); these findings were confirmed in subsequent replication studies (Palmer et al, 2012) and recent meta-analysis (Hao et al, 2013;Umar et al, 2013). Nevertheless, the ultimate role of this SNP in CRC development needs further investigation in large scale studies.…”

“…Rs2274223 of PLCE1 gene was found to have protective effect against CRC development in Chinese population (Li et al, 2012c;Wang et al, 2014), but no significant associations were reported for rs4072037 and rs2294008 variants (Li et al, 2012c;Smith et al, 2012). Recent meta-analysis have confirmed the role of these SNPs for the development of different cancers (Hao et al, 2013;Umar et al, 2013;Zheng et al, 2013), outlining the need of studies on CRC patients.…”